Ligand Pharmaceuticals (LGND) total liabilities

Total liabilities · fiscal 2025
$543.43M

Ligand Pharmaceuticals (LGND) had total liabilities of $543.43M at the end of fiscal 2025 (December 31, 2025). That is 388.1% higher than the $111.34M of fiscal 2024. Figures as of 19 Nov 2026, 00:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$543.43M
Change on fiscal 2024
+388.1%
Growth, 5 years
−3.6% a year
Growth, 10 years
+9.2% a year
Highest on record
$727.68Mfiscal 2019
Lowest on record
$55.10Mfiscal 2013
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Ligand Pharmaceuticals total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities shrank at a compound 3.6% a year; over ten years the rate was 9.2% a year. Across the 16 fiscal years on record (2010–2025), the highest was $727.68M in fiscal 2019 and the lowest $55.10M in fiscal 2013.

History · 16 fiscal years

Total liabilities by fiscal year

Ligand Pharmaceuticals total liabilities, year by year

Ligand Pharmaceuticals (LGND) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$543.43M 388.1% up
2024$111.34M 29.0% up
2023$86.30M 47.8% down
2022$165.18M 65.3% down
2021$476.43M 27.0% down
2020$652.76M 10.3% down
2019$727.68M 4.0% up
2018$699.89M 177.3% up
2017$252.37M 9.4% up
2016$230.73M 2.0% up
2015$226.15M 3.2% down
2014$233.62M 324.0% up
2013$55.10M 29.2% down
2012$77.78M 25.3% down
2011$104.05M 44.4% up
2010$72.06M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Ligand Pharmaceuticals and comparable companies
CompanyTotal liabilitiesFiscal year
RadNet RDNT$2.40B2025
Ligand Pharmaceuticals LGND$543.43M2025
Scholar Rock Holding SRRK$158.78M2025
Teleflex TFX$3.82B2025
Mirum Pharmaceuticals MIRM$528.12M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on LGND

Ligand Pharmaceuticals, figure by figure

Ligand Pharmaceuticals (LGND) overview: price, valuation and scorecardAll health care companies by market value

Ligand Pharmaceuticals total liabilities: questions and answers

How large are Ligand Pharmaceuticals's total liabilities?

Ligand Pharmaceuticals (LGND) had total liabilities of $543.43M at the end of fiscal 2025 (December 31, 2025). That is 388.1% higher than the $111.34M of fiscal 2024.

What is the growth rate of Ligand Pharmaceuticals's total liabilities?

Over the five fiscal years to 2025 total liabilities shrank at a compound 3.6% a year; over ten years the rate was 9.2% a year.

What are the highest and lowest total liabilities figures on record for Ligand Pharmaceuticals?

Across the 16 fiscal years on record (2010–2025), the highest was $727.68M in fiscal 2019 and the lowest $55.10M in fiscal 2013.

How is Ligand Pharmaceuticals's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Ligand Pharmaceuticals it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ligand Pharmaceuticals (LGND) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/LGND/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.